{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:28:10Z","timestamp":1792783690206,"version":"4.5.0"},"reference-count":185,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T00:00:00Z","timestamp":1627430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T00:00:00Z","timestamp":1627430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Youth Science Foundation of The First Hospital of Jilin University","award":["NO. JDYY102019010"],"award-info":[{"award-number":["NO. JDYY102019010"]}],"id":[{"id":"https:\/\/ror.org\/034haf133","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s10557-021-07229-4","type":"journal-article","created":{"date-parts":[[2021,7,28]],"date-time":"2021-07-28T03:03:04Z","timestamp":1627441384000},"page":"199-216","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["The Function and Regulation of Platelet P2Y12 Receptor"],"prefix":"10.1007","volume":"37","author":[{"given":"Xiaohua","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoxing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2668-9374","authenticated-orcid":false,"given":"Xia","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,28]]},"reference":[{"issue":"8","key":"7229_CR1","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/ni.2631","volume":"14","author":"C Wong","year":"2013","unstructured":"Wong C, et al. Nucleation of platelets with blood-borne pathogens on Kupffer cells precedes other innate immunity and contributes to bacterial clearance. Nat Immunol. 2013;14(8):785\u201392.","journal-title":"Nat Immunol"},{"issue":"3","key":"7229_CR2","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1124\/pr.117.014530","volume":"70","author":"J Yeung","year":"2018","unstructured":"Yeung J, Li W, Holinstat M. Platelet signaling and disease: targeted therapy for thrombosis and other related diseases. Pharmacol Rev. 2018;70(3):526\u201348.","journal-title":"Pharmacol Rev"},{"key":"7229_CR3","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.3389\/fimmu.2019.01731","volume":"10","author":"M Mezger","year":"2019","unstructured":"Mezger M, et al. Platelets and immune responses during thromboinflammation. Front Immunol. 2019;10:1731.","journal-title":"Front Immunol"},{"key":"7229_CR4","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.3389\/fimmu.2019.01590","volume":"10","author":"O Eriksson","year":"2019","unstructured":"Eriksson O, et al. The human platelet as an innate immune cell: interactions between activated platelets and the complement system. Front Immunol. 2019;10:1590.","journal-title":"Front Immunol"},{"key":"7229_CR5","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1111\/jth.12952","volume":"13","author":"M Cattaneo","year":"2015","unstructured":"Cattaneo M. P2Y12 receptors: structure and function. J Thromb Haemost. 2015;13:S10\u20136.","journal-title":"J Thromb Haemost"},{"issue":"6817","key":"7229_CR6","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/35051599","volume":"409","author":"G Hollopeter","year":"2001","unstructured":"Hollopeter G, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature. 2001;409(6817):202\u20137.","journal-title":"Nature"},{"issue":"11","key":"7229_CR7","doi-asserted-by":"publisher","first-page":"8608","DOI":"10.1074\/jbc.M009718200","volume":"276","author":"FL Zhang","year":"2001","unstructured":"Zhang FL, et al. ADP is the cognate ligand for the orphan G protein-coupled receptor SP1999. J Biol Chem. 2001;276(11):8608\u201315.","journal-title":"J Biol Chem"},{"issue":"1","key":"7229_CR8","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11302-012-9329-0","volume":"9","author":"P Ohlmann","year":"2013","unstructured":"Ohlmann P, et al. The platelet P2Y(12) receptor under normal and pathological conditions. Assessment with the radiolabeled selective antagonist [(3)H]PSB-0413. Purinergic Signal. 2013;9(1):59\u201366.","journal-title":"Purinergic Signal"},{"issue":"12","key":"7229_CR9","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1038\/nn1805","volume":"9","author":"SE Haynes","year":"2006","unstructured":"Haynes SE, et al. The P2Y12 receptor regulates microglial activation by extracellular nucleotides. Nat Neurosci. 2006;9(12):1512\u20139.","journal-title":"Nat Neurosci"},{"issue":"10","key":"7229_CR10","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1161\/01.ATV.0000142376.30582.ed","volume":"24","author":"AK Wihlborg","year":"2004","unstructured":"Wihlborg AK, et al. ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arterioscler Thromb Vasc Biol. 2004;24(10):1810\u20135.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"7229_CR11","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ijcard.2008.12.091","volume":"142","author":"C Hogberg","year":"2010","unstructured":"Hogberg C, et al. The reversible oral P2Y12 antagonist AZD6140 inhibits ADP-induced contractions in murine and human vasculature. Int J Cardiol. 2010;142(2):187\u201392.","journal-title":"Int J Cardiol"},{"issue":"10","key":"7229_CR12","doi-asserted-by":"publisher","first-page":"5900","DOI":"10.4049\/jimmunol.0901799","volume":"185","author":"A Ben Addi","year":"2010","unstructured":"Ben Addi A, et al. Role of the P2Y12 receptor in the modulation of murine dendritic cell function by ADP. J Immunol. 2010;185(10):5900\u20136.","journal-title":"J Immunol"},{"issue":"132","key":"7229_CR13","doi-asserted-by":"publisher","first-page":"ra55","DOI":"10.1126\/scisignal.2000588","volume":"3","author":"M Kronlage","year":"2010","unstructured":"Kronlage M, et al. Autocrine purinergic receptor signaling is essential for macrophage chemotaxis. Sci Signal. 2010;3(132):ra55.","journal-title":"Sci Signal"},{"issue":"2","key":"7229_CR14","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.jaci.2009.11.029","volume":"125","author":"JS Neves","year":"2010","unstructured":"Neves JS, Radke AL, Weller PF. Cysteinyl leukotrienes acting via granule membrane-expressed receptors elicit secretion from within cell-free human eosinophil granules. J Allergy Clin Immunol. 2010;125(2):477\u201382.","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"7229_CR15","doi-asserted-by":"publisher","first-page":"e0139805","DOI":"10.1371\/journal.pone.0139805","volume":"10","author":"VS Muniz","year":"2015","unstructured":"Muniz VS, et al. Purinergic P2Y12 receptor activation in eosinophils and the schistosomal host response. PLoS One. 2015;10(10):e0139805.","journal-title":"PLoS One"},{"issue":"10","key":"7229_CR16","doi-asserted-by":"publisher","first-page":"3579","DOI":"10.1172\/JCI38576","volume":"122","author":"X Su","year":"2012","unstructured":"Su X, et al. The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling. J Clin Invest. 2012;122(10):3579\u201392.","journal-title":"J Clin Invest"},{"issue":"11","key":"7229_CR17","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1096\/fj.201600616R","volume":"30","author":"A Mediero","year":"2016","unstructured":"Mediero A, et al. Ticagrelor regulates osteoblast and osteoclast function and promotes bone formation in vivo via an adenosine-dependent mechanism. FASEB J. 2016;30(11):3887\u2013900.","journal-title":"FASEB J"},{"issue":"1","key":"7229_CR18","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3390\/cancers12010250","volume":"12","author":"O Elaskalani","year":"2020","unstructured":"Elaskalani O, et al. Antiplatelet drug ticagrelor enhances chemotherapeutic efficacy by targeting the novel P2Y12-AKT pathway in pancreatic cancer cells. Cancers. 2020;12(1):250.","journal-title":"Cancers"},{"issue":"2","key":"7229_CR19","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s12032-013-0567-y","volume":"30","author":"S Sarangi","year":"2013","unstructured":"Sarangi S, et al. P2Y12 receptor inhibition augments cytotoxic effects of cisplatin in breast cancer. Med Oncol. 2013;30(2):567.","journal-title":"Med Oncol"},{"issue":"8","key":"7229_CR20","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1111\/j.1742-4658.2007.05741.x","volume":"274","author":"P Krzemi\u0144ski","year":"2007","unstructured":"Krzemi\u0144ski P, et al. Expression and functional characterization of P2Y1 and P2Y12 nucleotide receptors in long-term serum-deprived glioma C6 cells. FEBS J. 2007;274(8):1970\u201382.","journal-title":"FEBS J"},{"issue":"4","key":"7229_CR21","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/sj.bjp.0704114","volume":"133","author":"J Jin","year":"2001","unstructured":"Jin J, et al. The C6\u20132B glioma cell P2Y(AC) receptor is pharmacologically and molecularly identical to the platelet P2Y(12) receptor. Br J Pharmacol. 2001;133(4):521\u20138.","journal-title":"Br J Pharmacol"},{"issue":"3","key":"7229_CR22","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1046\/j.1365-2141.1998.01056.x","volume":"103","author":"B Hechler","year":"1998","unstructured":"Hechler B, et al. The P2Y1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel. Br J Haematol. 1998;103(3):858\u201366.","journal-title":"Br J Haematol"},{"issue":"4","key":"7229_CR23","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1074\/jbc.273.4.2030","volume":"273","author":"J Jin","year":"1998","unstructured":"Jin J, Daniel JL, Kunapuli SP. Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem. 1998;273(4):2030\u20134.","journal-title":"J Biol Chem"},{"issue":"12","key":"7229_CR24","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1182\/blood.V98.12.3340","volume":"98","author":"NA Turner","year":"2001","unstructured":"Turner NA, Moake JL, McIntire LV. Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow. Blood. 2001;98(12):3340\u20135.","journal-title":"Blood"},{"issue":"3","key":"7229_CR25","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s11302-012-9303-x","volume":"8","author":"C Gachet","year":"2012","unstructured":"Gachet C. P2Y(12) receptors in platelets and other hematopoietic and non-hematopoietic cells. Purinergic Signal. 2012;8(3):609\u201319.","journal-title":"Purinergic Signal"},{"issue":"5","key":"7229_CR26","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1182\/blood.V75.5.1081.1081","volume":"75","author":"M Cattaneo","year":"1990","unstructured":"Cattaneo M, et al. Released adenosine diphosphate stabilizes thrombin-induced human platelet aggregates. Blood. 1990;75(5):1081\u20136.","journal-title":"Blood"},{"issue":"4","key":"7229_CR27","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1046\/j.1365-2141.2000.02208.x","volume":"110","author":"RF Storey","year":"2000","unstructured":"Storey RF, et al. The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol. 2000;110(4):925\u201334.","journal-title":"Br J Haematol"},{"issue":"3","key":"7229_CR28","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1111\/j.1538-7836.2006.01789.x","volume":"4","author":"H Shankar","year":"2006","unstructured":"Shankar H, et al. P2Y12 receptor-mediated potentiation of thrombin-induced thromboxane A2 generation in platelets occurs through regulation of Erk1\/2 activation. J Thromb Haemost. 2006;4(3):638\u201347.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"7229_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.blre.2009.04.001","volume":"23","author":"P Blair","year":"2009","unstructured":"Blair P, Flaumenhaft R. Platelet alpha-granules: basic biology and clinical correlates. Blood Rev. 2009;23(4):177\u201389.","journal-title":"Blood Rev"},{"key":"7229_CR30","doi-asserted-by":"publisher","first-page":"406","DOI":"10.3389\/fimmu.2018.00406","volume":"9","author":"ED Ponomarev","year":"2018","unstructured":"Ponomarev ED. Fresh evidence for platelets as neuronal and innate immune cells: their role in the activation, differentiation, and deactivation of Th1, Th17, and Tregs during tissue inflammation. Front Immunol. 2018;9:406.","journal-title":"Front Immunol"},{"issue":"3","key":"7229_CR31","first-page":"490","volume":"114","author":"MR Thomas","year":"2015","unstructured":"Thomas MR, Storey RF. Effect of P2Y12 inhibitors on inflammation and immunity. Thromb Haemost. 2015;114(3):490\u20137.","journal-title":"Thromb Haemost"},{"issue":"12","key":"7229_CR32","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3390\/ph13120420","volume":"13","author":"R Anderson","year":"2020","unstructured":"Anderson R, et al. ADP-mediated upregulation of expression of CD62P on human platelets is critically dependent on co-activation of P2Y1 and P2Y12 receptors. Pharmaceuticals. 2020;13(12):420.","journal-title":"Pharmaceuticals"},{"issue":"2","key":"7229_CR33","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1159\/000339857","volume":"160","author":"J Suzuki","year":"2013","unstructured":"Suzuki J, et al. Cytokine secretion from human monocytes potentiated by P-selectin-mediated cell adhesion. Int Arch Allergy Immunol. 2013;160(2):152\u201360.","journal-title":"Int Arch Allergy Immunol"},{"issue":"10","key":"7229_CR34","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1161\/01.CIR.95.10.2387","volume":"95","author":"F Neumann","year":"1997","unstructured":"Neumann F, et al. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets. Circulation. 1997;95(10):2387\u201394.","journal-title":"Circulation"},{"issue":"4","key":"7229_CR35","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.celrep.2019.06.062","volume":"28","author":"A Carestia","year":"2019","unstructured":"Carestia A, et al. Platelets promote macrophage polarization toward pro-inflammatory phenotype and increase survival of septic mice. Cell Rep. 2019;28(4):896-908.e5.","journal-title":"Cell Rep"},{"issue":"3","key":"7229_CR36","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1161\/ATVBAHA.113.302919","volume":"34","author":"S Badrnya","year":"2014","unstructured":"Badrnya S, et al. Platelets mediate oxidized low-density lipoprotein-induced monocyte extravasation and foam cell formation. Arterioscler Thromb Vasc Biol. 2014;34(3):571\u201380.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"7229_CR37","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1182\/blood-2015-01-624023","volume":"126","author":"J Etulain","year":"2015","unstructured":"Etulain J, et al. P-selectin promotes neutrophil extracellular trap formation in mice. Blood. 2015;126(2):242\u20136.","journal-title":"Blood"},{"issue":"11","key":"7229_CR38","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1111\/j.1538-7836.2005.01603.x","volume":"3","author":"M Barnard","year":"2005","unstructured":"Barnard M, et al. Effects of platelet binding on whole blood flow cytometry assays of monocyte and neutrophil procoagulant activity. J Thromb Haemost. 2005;3(11):2563\u201370.","journal-title":"J Thromb Haemost"},{"issue":"3","key":"7229_CR39","first-page":"568","volume":"94","author":"V Evangelista","year":"2005","unstructured":"Evangelista V, et al. Clopidogrel inhibits platelet-leukocyte adhesion and platelet-dependent leukocyte activation. Thromb Haemost. 2005;94(3):568\u201377.","journal-title":"Thromb Haemost"},{"issue":"06","key":"7229_CR40","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1160\/TH11-12-0867","volume":"107","author":"L Totani","year":"2012","unstructured":"Totani L, et al. Prasugrel inhibits platelet-leukocyte interaction and reduces inflammatory markers in a model of endotoxic shock in the mouse. Thromb Haemost. 2012;107(06):1130\u201340.","journal-title":"Thromb Haemost"},{"issue":"10","key":"7229_CR41","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1161\/01.ATV.0000092127.16125.E6","volume":"23","author":"C Leon","year":"2003","unstructured":"Leon C, et al. Differential involvement of the P2Y1 and P2Y12 receptors in platelet procoagulant activity. Arterioscler Thromb Vasc Biol. 2003;23(10):1941\u20137.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"5","key":"7229_CR42","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1111\/j.1538-7836.2004.00692.x","volume":"2","author":"RT Dorsam","year":"2004","unstructured":"Dorsam RT, Tuluc M, Kunapuli SP. Role of protease-activated and ADP receptor subtypes in thrombin generation on human platelets. J Thromb Haemost. 2004;2(5):804\u201312.","journal-title":"J Thromb Haemost"},{"issue":"6","key":"7229_CR43","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1160\/TH04-09-0597","volume":"93","author":"PE van der Meijden","year":"2005","unstructured":"van der Meijden PE, et al. Platelet P2Y12 receptors enhance signalling towards procoagulant activity and thrombin generation. A study with healthy subjects and patients at thrombotic risk. Thromb Haemost. 2005;93(6):1128\u201336.","journal-title":"Thromb Haemost"},{"issue":"2","key":"7229_CR44","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1182\/blood-2003-05-1385","volume":"103","author":"C Leon","year":"2004","unstructured":"Leon C, et al. Platelet ADP receptors contribute to the initiation of intravascular coagulation. Blood. 2004;103(2):594\u2013600.","journal-title":"Blood"},{"issue":"17","key":"7229_CR45","doi-asserted-by":"publisher","first-page":"6065","DOI":"10.3390\/ijms21176065","volume":"21","author":"A G\u0105secka","year":"2020","unstructured":"G\u0105secka A, et al. Role of P2Y receptors in platelet extracellular vesicle release. Int J Mol Sci. 2020;21(17):6065.","journal-title":"Int J Mol Sci"},{"issue":"5\u20136","key":"7229_CR46","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s10557-017-6757-7","volume":"31","author":"J Rosinska","year":"2017","unstructured":"Rosinska J, Lukasik M, Kozubski W. The impact of vascular disease treatment on platelet-derived microvesicles. Cardiovasc Drugs Ther. 2017;31(5\u20136):627\u201344.","journal-title":"Cardiovasc Drugs Ther"},{"key":"7229_CR47","doi-asserted-by":"publisher","first-page":"314","DOI":"10.3389\/fphar.2016.00314","volume":"7","author":"A Giacomazzi","year":"2016","unstructured":"Giacomazzi A, et al. Antiplatelet agents inhibit the generation of platelet-derived microparticles. Front Pharmacol. 2016;7:314.","journal-title":"Front Pharmacol"},{"issue":"6","key":"7229_CR48","doi-asserted-by":"publisher","first-page":"782","DOI":"10.5603\/CJ.a2018.0045","volume":"26","author":"A Gasecka","year":"2019","unstructured":"Gasecka A, et al. P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets. Cardiol J. 2019;26(6):782\u20139.","journal-title":"Cardiol J"},{"issue":"2","key":"7229_CR49","first-page":"331","volume":"110","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, et al. Contact- and agonist-regulated microvesiculation of human platelets. Thromb Haemost. 2013;110(2):331\u20139.","journal-title":"Thromb Haemost"},{"issue":"3","key":"7229_CR50","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1253\/circj.CJ-11-1145","volume":"76","author":"CN Fran\u00e7a","year":"2012","unstructured":"Fran\u00e7a CN, et al. Endothelial progenitor cell mobilization and platelet microparticle release are influenced by clopidogrel plasma levels in stable coronary artery disease. Circ J. 2012;76(3):729\u201336.","journal-title":"Circ J"},{"issue":"5","key":"7229_CR51","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3109\/09537104.2014.940304","volume":"26","author":"S Kafian","year":"2015","unstructured":"Kafian S, et al. Association between platelet reactivity and circulating platelet-derived microvesicles in patients with acute coronary syndrome. Platelets. 2015;26(5):467\u201373.","journal-title":"Platelets"},{"issue":"2","key":"7229_CR52","doi-asserted-by":"publisher","first-page":"121","DOI":"10.3109\/09537104.2011.597527","volume":"23","author":"KI Kalantzi","year":"2012","unstructured":"Kalantzi KI, et al. The platelet hyporesponsiveness to clopidogrel in acute coronary syndrome patients treated with 75 mg\/day clopidogrel may be overcome within 1 month of treatment. Platelets. 2012;23(2):121\u201331.","journal-title":"Platelets"},{"issue":"3","key":"7229_CR53","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1111\/jth.14689","volume":"18","author":"A Gasecka","year":"2020","unstructured":"Gasecka A, et al. Ticagrelor attenuates the increase of extracellular vesicle concentrations in plasma after acute myocardial infarction compared to clopidogrel. J Thromb Haemost. 2020;18(3):609\u201323.","journal-title":"J Thromb Haemost"},{"key":"7229_CR54","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.metabol.2018.04.008","volume":"85","author":"A Hafiane","year":"2018","unstructured":"Hafiane A, Daskalopoulou SS. Extracellular vesicles characteristics and emerging roles in atherosclerotic cardiovascular disease. Metabolism. 2018;85:213\u201322.","journal-title":"Metabolism"},{"issue":"2","key":"7229_CR55","doi-asserted-by":"publisher","first-page":"264","DOI":"10.7150\/ijms.28580","volume":"16","author":"B Chyrchel","year":"2019","unstructured":"Chyrchel B, et al. Platelet reactivity and circulating platelet-derived microvesicles are differently affected by P2Y12 receptor antagonists. Int J Med Sci. 2019;16(2):264\u201375.","journal-title":"Int J Med Sci"},{"issue":"1","key":"7229_CR56","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/jth.12063","volume":"11","author":"S Zhang","year":"2013","unstructured":"Zhang S, et al. P2Y12 protects platelets from apoptosis via PI3k-dependent Bak\/Bax inactivation. J Thromb Haemost. 2013;11(1):149\u201360.","journal-title":"J Thromb Haemost"},{"issue":"10","key":"7229_CR57","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1097\/CAD.0000000000000925","volume":"31","author":"X Meng","year":"2020","unstructured":"Meng X, et al. Ticagrelor prevents tumor metastasis via inhibiting cell proliferation and promoting platelet apoptosis. Anticancer Drugs. 2020;31(10):1012\u20137.","journal-title":"Anticancer Drugs"},{"issue":"10","key":"7229_CR58","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1182\/blood-2014-09-598722","volume":"126","author":"MM Ouseph","year":"2015","unstructured":"Ouseph MM, et al. Autophagy is induced upon platelet activation and is essential for hemostasis and thrombosis. Blood. 2015;126(10):1224\u201333.","journal-title":"Blood"},{"issue":"8","key":"7229_CR59","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1111\/j.1538-7836.2009.03492.x","volume":"7","author":"E Malaver","year":"2009","unstructured":"Malaver E, et al. NF-kappaB inhibitors impair platelet activation responses. J Thromb Haemost. 2009;7(8):1333\u201343.","journal-title":"J Thromb Haemost"},{"issue":"11","key":"7229_CR60","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1182\/blood.V80.11.2787.2787","volume":"80","author":"M Cattaneo","year":"1992","unstructured":"Cattaneo M, et al. Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate. Blood. 1992;80(11):2787\u201396.","journal-title":"Blood"},{"issue":"4","key":"7229_CR61","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1172\/JCI117835","volume":"95","author":"P Nurden","year":"1995","unstructured":"Nurden P, et al. An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets. Its influence on glycoprotein IIb-IIIa complex function. J Clin Invest. 1995;95(4):1612\u201322.","journal-title":"J Clin Invest"},{"issue":"11","key":"7229_CR62","doi-asserted-by":"publisher","first-page":"E101","DOI":"10.1161\/01.ATV.20.11.e101","volume":"20","author":"M Cattaneo","year":"2000","unstructured":"Cattaneo M, et al. Platelets from a patient heterozygous for the defect of P2CYC receptors for ADP have a secretion defect despite normal thromboxane A2 production and normal granule stores: further evidence that some cases of platelet \u2018primary secretion defect\u2019 are heterozygous for a defect of P2CYC receptors. Arterioscler Thromb Vasc Biol. 2000;20(11):E101\u20136.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"7229_CR63","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1073\/pnas.0437879100","volume":"100","author":"M Cattaneo","year":"2003","unstructured":"Cattaneo M, et al. Molecular bases of defective signal transduction in the platelet P2Y12 receptor of a patient with congenital bleeding. Proc Natl Acad Sci U S A. 2003;100(4):1978\u201383.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"7229_CR64","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1111\/j.1538-7836.2005.01554.x","volume":"3","author":"M Shiraga","year":"2005","unstructured":"Shiraga M, et al. Impaired platelet function in a patient with P2Y12 deficiency caused by a mutation in the translation initiation codon. J Thromb Haemost. 2005;3(10):2315\u201323.","journal-title":"J Thromb Haemost"},{"issue":"17","key":"7229_CR65","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1182\/blood-2008-11-190850","volume":"113","author":"ME Daly","year":"2009","unstructured":"Daly ME, et al. Identification and characterization of a novel P2Y 12 variant in a patient diagnosed with type 1 von Willebrand disease in the European MCMDM-1VWD study. Blood. 2009;113(17):4110\u20133.","journal-title":"Blood"},{"issue":"20","key":"7229_CR66","doi-asserted-by":"publisher","first-page":"5641","DOI":"10.1182\/blood-2011-02-336826","volume":"118","author":"S Nisar","year":"2011","unstructured":"Nisar S, et al. An intact PDZ motif is essential for correct P2Y12 purinoceptor traffic in human platelets. Blood. 2011;118(20):5641\u201351.","journal-title":"Blood"},{"issue":"5","key":"7229_CR67","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1111\/jth.12539","volume":"12","author":"YM Patel","year":"2014","unstructured":"Patel YM, et al. A novel mutation in the P2Y12 receptor and a function-reducing polymorphism in protease-activated receptor 1 in a patient with chronic bleeding. J Thromb Haemost. 2014;12(5):716\u201325.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"7229_CR68","doi-asserted-by":"publisher","first-page":"279","DOI":"10.5482\/HAMO-16-03-0010","volume":"36","author":"A Lecchi","year":"2016","unstructured":"Lecchi A, et al. Inherited dysfunctional platelet P2Y(12) receptor mutations associated with bleeding disorders. Hamostaseologie. 2016;36(4):279\u201383.","journal-title":"Hamostaseologie"},{"issue":"1","key":"7229_CR69","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/jth.13900","volume":"16","author":"SJ Mundell","year":"2018","unstructured":"Mundell SJ, et al. Receptor homodimerization plays a critical role in a novel dominant negative P2RY12 variant identified in a family with severe bleeding. J Thromb Haemost. 2018;16(1):44\u201353.","journal-title":"J Thromb Haemost"},{"issue":"7498","key":"7229_CR70","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nature13083","volume":"509","author":"K Zhang","year":"2014","unstructured":"Zhang K, et al. Structure of the human P2Y12 receptor in complex with an antithrombotic drug. Nature. 2014;509(7498):115\u20138.","journal-title":"Nature"},{"issue":"2","key":"7229_CR71","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s00018-018-2937-2","volume":"76","author":"Y Gao","year":"2018","unstructured":"Gao Y, et al. The role of P2Y12 receptor in ischemic stroke of atherosclerotic origin. Cell Mol Life Sci. 2018;76(2):341\u201354.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"7229_CR72","doi-asserted-by":"publisher","first-page":"9955","DOI":"10.1038\/s41598-018-28181-8","volume":"8","author":"Y Ito","year":"2018","unstructured":"Ito Y, et al. Vasodilator-stimulated phosphoprotein (VASP) is not a major mediator of platelet aggregation, thrombogenesis, haemostasis, and antiplatelet effect of prasugrel in rats. Sci Rep. 2018;8(1):9955.","journal-title":"Sci Rep"},{"issue":"1","key":"7229_CR73","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1182\/blood-2002-11-3417","volume":"103","author":"S Massberg","year":"2004","unstructured":"Massberg S, et al. Enhanced in vivo platelet adhesion in vasodilator-stimulated phosphoprotein (VASP)-deficient mice. Blood. 2004;103(1):136\u201342.","journal-title":"Blood"},{"issue":"1","key":"7229_CR74","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/emboj\/18.1.37","volume":"18","author":"A Asz\u00f3di","year":"1999","unstructured":"Asz\u00f3di A, et al. The vasodilator-stimulated phosphoprotein (VASP) is involved in cGMP- and cAMP-mediated inhibition of agonist-induced platelet aggregation, but is dispensable for smooth muscle function. Embo j. 1999;18(1):37\u201348.","journal-title":"Embo j"},{"issue":"3","key":"7229_CR75","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1055\/s-0037-1614344","volume":"82","author":"UR Schwarz","year":"1999","unstructured":"Schwarz UR, et al. Flow cytometry analysis of intracellular VASP phosphorylation for the assessment of activating and inhibitory signal transduction pathways in human platelets\u2013definition and detection of ticlopidine\/clopidogrel effects. Thromb Haemost. 1999;82(3):1145\u201352.","journal-title":"Thromb Haemost"},{"issue":"12","key":"7229_CR76","doi-asserted-by":"publisher","first-page":"4156","DOI":"10.1182\/blood.V94.12.4156","volume":"94","author":"C Trumel","year":"1999","unstructured":"Trumel C, et al. A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1-activating peptide through the late activation of phosphoinositide 3-kinase. Blood. 1999;94(12):4156\u201365.","journal-title":"Blood"},{"issue":"26","key":"7229_CR77","doi-asserted-by":"publisher","first-page":"23382","DOI":"10.1074\/jbc.M202212200","volume":"277","author":"D Woulfe","year":"2002","unstructured":"Woulfe D, et al. Activation of Rap1B by G(i) family members in platelets. J Biol Chem. 2002;277(26):23382\u201390.","journal-title":"J Biol Chem"},{"issue":"7","key":"7229_CR78","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1182\/blood-2010-08-263111","volume":"117","author":"M Cattaneo","year":"2011","unstructured":"Cattaneo M. The platelet P2Y(1)(2) receptor for adenosine diphosphate: congenital and drug-induced defects. Blood. 2011;117(7):2102\u201312.","journal-title":"Blood"},{"issue":"2","key":"7229_CR79","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1042\/BJ20100166","volume":"429","author":"A Garcia","year":"2010","unstructured":"Garcia A, et al. Role of phosphoinositide 3-kinase beta in platelet aggregation and thromboxane A2 generation mediated by Gi signalling pathways. Biochem J. 2010;429(2):369\u201377.","journal-title":"Biochem J"},{"issue":"21","key":"7229_CR80","first-page":"2250","volume":"360","author":"J Miao","year":"2009","unstructured":"Miao J, Liu R, Li Z. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360(21):2250\u20131.","journal-title":"N Engl J Med"},{"issue":"7","key":"7229_CR81","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/sj.bjp.0703237","volume":"129","author":"A Sugidachi","year":"2000","unstructured":"Sugidachi A, et al. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. Br J Pharmacol. 2000;129(7):1439\u201346.","journal-title":"Br J Pharmacol"},{"issue":"15","key":"7229_CR82","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1001\/jama.2021.0716","volume":"325","author":"H Kamran","year":"2021","unstructured":"Kamran H, et al. Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review. JAMA. 2021;325(15):1545\u201355.","journal-title":"JAMA"},{"issue":"16","key":"7229_CR83","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1001\/jama.2020.16167","volume":"324","author":"S You","year":"2020","unstructured":"You S, et al. Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. JAMA. 2020;324(16):1640\u201350.","journal-title":"JAMA"},{"issue":"2","key":"7229_CR84","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1177\/1074248413511693","volume":"19","author":"D Armstrong","year":"2014","unstructured":"Armstrong D, et al. Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. J Cardiovasc Pharmacol Ther. 2014;19(2):209\u201319.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"14","key":"7229_CR85","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1161\/CIRCULATIONAHA.118.038317","volume":"139","author":"F Franchi","year":"2019","unstructured":"Franchi F, et al. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation. 2019;139(14):1661\u201370.","journal-title":"Circulation"},{"issue":"2","key":"7229_CR86","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1161\/CIRCRESAHA.118.313591","volume":"124","author":"D Wolf","year":"2019","unstructured":"Wolf D, Ley K. Immunity and Inflammation in Atherosclerosis. Circ Res. 2019;124(2):315\u201327.","journal-title":"Circ Res"},{"issue":"3","key":"7229_CR87","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1160\/TH06-07-0415","volume":"97","author":"SM Penz","year":"2007","unstructured":"Penz SM, et al. Glycoprotein Ibalpha inhibition and ADP receptor antagonists, but not aspirin, reduce platelet thrombus formation in flowing blood exposed to atherosclerotic plaques. Thromb Haemost. 2007;97(3):435\u201343.","journal-title":"Thromb Haemost"},{"issue":"4","key":"7229_CR88","doi-asserted-by":"publisher","first-page":"e10130","DOI":"10.1371\/journal.pone.0010130","volume":"5","author":"R Nergiz-Unal","year":"2010","unstructured":"Nergiz-Unal R, et al. Stabilizing role of platelet P2Y(12) receptors in shear-dependent thrombus formation on ruptured plaques. PLoS One. 2010;5(4):e10130.","journal-title":"PLoS One"},{"issue":"3","key":"7229_CR89","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.mvr.2009.01.009","volume":"77","author":"A Afek","year":"2009","unstructured":"Afek A, et al. Clopidogrel attenuates atheroma formation and induces a stable plaque phenotype in apolipoprotein E knockout mice. Microvasc Res. 2009;77(3):364\u20139.","journal-title":"Microvasc Res"},{"issue":"5","key":"7229_CR90","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s00380-015-0696-7","volume":"31","author":"C Heim","year":"2016","unstructured":"Heim C, et al. Clopidogrel significantly lowers the development of atherosclerosis in ApoE-deficient mice in vivo. Heart Vessels. 2016;31(5):783\u201394.","journal-title":"Heart Vessels"},{"key":"7229_CR91","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.atherosclerosis.2018.05.053","volume":"275","author":"B Ganbaatar","year":"2018","unstructured":"Ganbaatar B, et al. Ticagrelor, a P2Y12 antagonist, attenuates vascular dysfunction and inhibits atherogenesis in apolipoprotein-E-deficient mice. Atherosclerosis. 2018;275:124\u201332.","journal-title":"Atherosclerosis"},{"issue":"8","key":"7229_CR92","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1161\/ATVBAHA.111.239095","volume":"32","author":"D Li","year":"2012","unstructured":"Li D, et al. Roles of purinergic receptor P2Y, G protein-coupled 12 in the development of atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2012;32(8):e81\u20139.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"7229_CR93","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1093\/cvr\/cvu028","volume":"102","author":"LE West","year":"2014","unstructured":"West LE, et al. Vessel wall, not platelet, P2Y12 potentiates early atherogenesis. Cardiovasc Res. 2014;102(3):429\u201335.","journal-title":"Cardiovasc Res"},{"issue":"4","key":"7229_CR94","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1080\/15548627.2020.1741202","volume":"17","author":"S Pi","year":"2021","unstructured":"Pi S, et al. The P2RY12 receptor promotes VSMC-derived foam cell formation by inhibiting autophagy in advanced atherosclerosis. Autophagy. 2021;17(4):980\u20131000.","journal-title":"Autophagy"},{"issue":"1","key":"7229_CR95","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1161\/ATVBAHA.116.308561","volume":"37","author":"X Chen","year":"2017","unstructured":"Chen X, et al. Endothelial Cell-Specific Deletion of P2Y2 Receptor Promotes Plaque Stability in Atherosclerosis-Susceptible ApoE-Null Mice. Arterioscler Thromb Vasc Biol. 2017;37(1):75\u201383.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"7229_CR96","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1111\/j.1538-7836.2010.04144.x","volume":"9","author":"GL Mendolicchio","year":"2011","unstructured":"Mendolicchio GL, et al. Variable effect of P2Y12 inhibition on platelet thrombus volume in flowing blood. J Thromb Haemost. 2011;9(2):373\u201382.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"7229_CR97","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1097\/00029330-200601010-00006","volume":"119","author":"Y Chen","year":"2006","unstructured":"Chen Y, et al. Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome. Chin Med J. 2006;119(1):32\u20136.","journal-title":"Chin Med J"},{"issue":"2","key":"7229_CR98","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s11239-017-1516-y","volume":"44","author":"A Lowenstern","year":"2017","unstructured":"Lowenstern A, et al. Platelet-related biomarkers and their response to inhibition with aspirin and p2y(12)-receptor antagonists in patients with acute coronary syndrome. J Thromb Thrombolysis. 2017;44(2):145\u201353.","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"7229_CR99","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.atherosclerosis.2010.10.030","volume":"214","author":"T Sakata","year":"2011","unstructured":"Sakata T, Kario K. Antiplatelet therapy effectively reduces plasma plasminogen activator inhibitor-1 levels. Atherosclerosis. 2011;214(2):490\u20131.","journal-title":"Atherosclerosis"},{"issue":"7","key":"7229_CR100","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1016\/j.jstrokecerebrovasdis.2014.01.022","volume":"23","author":"X Yi","year":"2014","unstructured":"Yi X, et al. A comparative study of dual versus monoantiplatelet therapy in patients with acute large-artery atherosclerosis stroke. J Stroke Cerebrovasc Dis. 2014;23(7):1975\u201381.","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"21","key":"7229_CR101","doi-asserted-by":"publisher","first-page":"e009600","DOI":"10.1161\/JAHA.118.009600","volume":"7","author":"X An","year":"2018","unstructured":"An X, et al. Inhibition of platelets by clopidogrel suppressed Ang II-induced vascular inflammation, oxidative stress, and remodeling. J Am Heart Assoc. 2018;7(21):e009600.","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"7229_CR102","doi-asserted-by":"publisher","first-page":"e51707","DOI":"10.1371\/journal.pone.0051707","volume":"7","author":"O Liu","year":"2012","unstructured":"Liu O, et al. Clopidogrel, a platelet P2Y12 receptor inhibitor, reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. PLoS One. 2012;7(12):e51707.","journal-title":"PLoS One"},{"key":"7229_CR103","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.thromres.2018.04.007","volume":"166","author":"Y Wang","year":"2018","unstructured":"Wang Y, et al. Platelet activation and antiplatelet therapy in sepsis: A narrative review. Thromb Res. 2018;166:28\u201336.","journal-title":"Thromb Res"},{"key":"7229_CR104","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.3389\/fimmu.2019.01687","volume":"10","author":"A Assinger","year":"2019","unstructured":"Assinger A, et al. Platelets in sepsis: an update on experimental models and clinical data. Front Immunol. 2019;10:1687.","journal-title":"Front Immunol"},{"issue":"11","key":"7229_CR105","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1097\/01.CCM.0000186414.86162.03","volume":"33","author":"AO Soriano","year":"2005","unstructured":"Soriano AO, et al. Levels of endothelial and platelet microparticles and their interactions with leukocytes negatively correlate with organ dysfunction and predict mortality in severe sepsis. Crit Care Med. 2005;33(11):2540\u20136.","journal-title":"Crit Care Med"},{"issue":"4","key":"7229_CR106","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2174\/1874467211666180619124531","volume":"11","author":"ACA Naime","year":"2018","unstructured":"Naime ACA, Ganaes JOF, Lopes-Pires ME. Sepsis: the involvement of platelets and the current treatments. Curr Mol Pharmacol. 2018;11(4):261\u20139.","journal-title":"Curr Mol Pharmacol"},{"key":"7229_CR107","doi-asserted-by":"publisher","first-page":"82","DOI":"10.3389\/fimmu.2015.00082","volume":"6","author":"H Hamzeh-Cognasse","year":"2015","unstructured":"Hamzeh-Cognasse H, et al. Platelets and infections - complex interactions with bacteria. Front Immunol. 2015;6:82.","journal-title":"Front Immunol"},{"key":"7229_CR108","doi-asserted-by":"publisher","first-page":"863","DOI":"10.3389\/fphar.2020.00863","volume":"11","author":"N Hannachi","year":"2020","unstructured":"Hannachi N, et al. Antiplatelet agents have a distinct efficacy on platelet aggregation induced by infectious bacteria. Front Pharmacol. 2020;11:863.","journal-title":"Front Pharmacol"},{"issue":"4","key":"7229_CR109","doi-asserted-by":"publisher","first-page":"e22279","DOI":"10.1002\/jbt.22279","volume":"33","author":"XL Wang","year":"2019","unstructured":"Wang XL, et al. Clopidogrel reduces lipopolysaccharide-induced inflammation and neutrophil-platelet aggregates in an experimental endotoxemic model. J Biochem Mol Toxicol. 2019;33(4):e22279.","journal-title":"J Biochem Mol Toxicol"},{"issue":"4","key":"7229_CR110","doi-asserted-by":"publisher","first-page":"257","DOI":"10.3109\/09537104.2013.809520","volume":"25","author":"M Rahman","year":"2014","unstructured":"Rahman M, et al. Ticagrelor reduces neutrophil recruitment and lung damage in abdominal sepsis. Platelets. 2014;25(4):257\u201363.","journal-title":"Platelets"},{"issue":"5","key":"7229_CR111","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1161\/ATVBAHA.116.307401","volume":"36","author":"E Liverani","year":"2016","unstructured":"Liverani E, et al. P2Y12 receptor modulates sepsis-induced inflammation. Arterioscler Thromb Vasc Biol. 2016;36(5):961\u201371.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"7229_CR112","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/09537104.2017.1392499","volume":"30","author":"X Li","year":"2018","unstructured":"Li X, et al. The protective effect of ticagrelor on renal function in a mouse model of sepsis-induced acute kidney injury. Platelets. 2018;30(2):199\u2013205.","journal-title":"Platelets"},{"issue":"6","key":"7229_CR113","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1111\/j.1538-7836.2009.03352.x","volume":"7","author":"M Seidel","year":"2009","unstructured":"Seidel M, et al. Beneficial effect of clopidogrel in a mouse model of polymicrobial sepsis. J Thromb Haemost. 2009;7(6):1030\u20132.","journal-title":"J Thromb Haemost"},{"issue":"2","key":"7229_CR114","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1189\/jlb.1012518","volume":"95","author":"E Liverani","year":"2014","unstructured":"Liverani E, et al. LPS-induced systemic inflammation is more severe in P2Y12 null mice. J Leukoc Biol. 2014;95(2):313\u201323.","journal-title":"J Leukoc Biol"},{"issue":"2","key":"7229_CR115","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1159\/000494147","volume":"11","author":"TAM Claushuis","year":"2019","unstructured":"Claushuis TAM, et al. Platelet-dense granules worsen pre-infection thrombocytopenia during gram-negative pneumonia-derived sepsis. J Innate Immun. 2019;11(2):168\u201380.","journal-title":"J Innate Immun"},{"issue":"1","key":"7229_CR116","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/JLB.3A0220-097R","volume":"110","author":"S Albayati","year":"2020","unstructured":"Albayati S, et al. P2Y(12) antagonism results in altered interactions between platelets and regulatory T cells during sepsis. J Leukoc Biol. 2020;110(1):141\u201353.","journal-title":"J Leukoc Biol"},{"issue":"12","key":"7229_CR117","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1161\/ATVBAHA.115.306528","volume":"35","author":"MR Thomas","year":"2015","unstructured":"Thomas MR, et al. Platelet P2Y12 inhibitors reduce systemic inflammation and its prothrombotic effects in an experimental human model. Arterioscler Thromb Vasc Biol. 2015;35(12):2562\u201370.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"7229_CR118","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1042\/CS20150591","volume":"130","author":"C Schoergenhofer","year":"2016","unstructured":"Schoergenhofer C, et al. Potent irreversible P2Y12 inhibition does not reduce LPS-induced coagulation activation in a randomized, double-blind, placebo-controlled trial. Clin Sci. 2016;130(6):433\u201340.","journal-title":"Clin Sci"},{"issue":"9","key":"7229_CR119","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1160\/TH16-10-0799","volume":"117","author":"D Kiers","year":"2017","unstructured":"Kiers D, et al. A randomised trial on the effect of anti-platelet therapy on the systemic inflammatory response in human endotoxaemia. Thromb Haemost. 2017;117(9):1798\u2013807.","journal-title":"Thromb Haemost"},{"issue":"1","key":"7229_CR120","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13613-018-0378-6","volume":"8","author":"A Dewitte","year":"2018","unstructured":"Dewitte A, et al. Correction to: Blood platelets and sepsis pathophysiology: A new therapeutic prospect in critically ill patients? Ann Intensive Care. 2018;8(1):32.","journal-title":"Ann Intensive Care"},{"issue":"4","key":"7229_CR121","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.jacbts.2018.05.005","volume":"3","author":"TR Sexton","year":"2018","unstructured":"Sexton TR, et al. Ticagrelor reduces thromboinflammatory markers in patients with pneumonia. JACC Basic Transl Sci. 2018;3(4):435\u201349.","journal-title":"JACC Basic Transl Sci"},{"issue":"5","key":"7229_CR122","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1007\/s00134-015-3760-y","volume":"41","author":"MJ Tsai","year":"2015","unstructured":"Tsai MJ, et al. Association of prior antiplatelet agents with mortality in sepsis patients: a nationwide population-based cohort study. Intensive Care Med. 2015;41(5):806\u201313.","journal-title":"Intensive Care Med"},{"issue":"2","key":"7229_CR123","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/ene.13801","volume":"26","author":"T Kim","year":"2019","unstructured":"Kim T, et al. Clopidogrel may decrease the risk of post-stroke infection after ischaemic stroke. Eur J Neurol. 2019;26(2):261\u20137.","journal-title":"Eur J Neurol"},{"key":"7229_CR124","unstructured":"Butt J, et al. Ticagrelor and the risk of staphylococcus aureus bacteremia and other infections. Eur Heart J Cardiovasc Pharmacother. 2020. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32750138\/Ticagrelor and The Risk of Staphylococcus Aureus Bacteremia and Other Infections. Accessed 4 Aug 2020."},{"issue":"7","key":"7229_CR125","doi-asserted-by":"publisher","first-page":"517","DOI":"10.3109\/09537104.2013.842965","volume":"25","author":"R Storey","year":"2014","unstructured":"Storey R, et al. Lower mortality following pulmonary adverse events and sepsis with ticagrelor compared to clopidogrel in the PLATO study. Platelets. 2014;25(7):517\u201325.","journal-title":"Platelets"},{"key":"7229_CR126","doi-asserted-by":"crossref","unstructured":"Long H, et al. Risk of infections in patients treated with ticagrelor versus clopidogrel: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2021;7(3):171\u20139.","DOI":"10.1093\/ehjcvp\/pvaa065"},{"issue":"5","key":"7229_CR127","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1038\/s41423-020-0444-5","volume":"18","author":"B Huang","year":"2020","unstructured":"Huang B, et al. Ticagrelor inhibits the NLRP3 inflammasome to protect against inflammatory disease independent of the P2Y(12) signaling pathway. Cell Mol Immunol. 2020;18(5):1278\u201389.","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"7229_CR128","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1001\/jamacardio.2019.1189","volume":"4","author":"P Lancellotti","year":"2019","unstructured":"Lancellotti P, et al. Antibacterial activity of ticagrelor in conventional antiplatelet dosages against antibiotic-resistant gram-positive bacteria. JAMA Cardiol. 2019;4(6):596\u20139.","journal-title":"JAMA Cardiol"},{"issue":"7","key":"7229_CR129","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/cancers9070094","volume":"9","author":"O Elaskalani","year":"2017","unstructured":"Elaskalani O, et al. Targeting platelets for the treatment of cancer. Cancers (Basel). 2017;9(7):94.","journal-title":"Cancers (Basel)."},{"key":"7229_CR130","doi-asserted-by":"publisher","first-page":"S106","DOI":"10.1016\/j.thromres.2017.12.016","volume":"164","author":"P Gresele","year":"2018","unstructured":"Gresele P, Malvestiti M, Momi S. Anti-platelet treatments in cancer: Basic and clinical research. Thromb Res. 2018;164:S106\u201311.","journal-title":"Thromb Res"},{"issue":"10","key":"7229_CR131","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1182\/blood-2017-02-769893","volume":"130","author":"MS Cho","year":"2017","unstructured":"Cho MS, et al. Role of ADP receptors on platelets in the growth of ovarian cancer. Blood. 2017;130(10):1235\u201342.","journal-title":"Blood"},{"issue":"2","key":"7229_CR132","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3109\/09537100903470298","volume":"21","author":"NM Bambace","year":"2010","unstructured":"Bambace NM, Levis JE, Holmes CE. The effect of P2Y-mediated platelet activation on the release of VEGF and endostatin from platelets. Platelets. 2010;21(2):85\u201393.","journal-title":"Platelets"},{"issue":"5","key":"7229_CR133","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1182\/blood-2011-02-334524","volume":"118","author":"EM Battinelli","year":"2011","unstructured":"Battinelli EM, Markens BA, Italiano JE Jr. Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. Blood. 2011;118(5):1359\u201369.","journal-title":"Blood"},{"issue":"8","key":"7229_CR134","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/iub.1406","volume":"67","author":"H Wu","year":"2015","unstructured":"Wu H, et al. The angiogenic responses induced by release of angiogenic proteins from tumor cell-activated platelets are regulated by distinct molecular pathways. IUBMB Life. 2015;67(8):626\u201333.","journal-title":"IUBMB Life"},{"issue":"7","key":"7229_CR135","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3109\/09537104.2016.1171302","volume":"27","author":"CE Holmes","year":"2016","unstructured":"Holmes CE, et al. Platelet phenotype changes associated with breast cancer and its treatment. Platelets. 2016;27(7):703\u201311.","journal-title":"Platelets"},{"issue":"5","key":"7229_CR136","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.ccr.2011.09.009","volume":"20","author":"M Labelle","year":"2011","unstructured":"Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell. 2011;20(5):576\u201390.","journal-title":"Cancer Cell"},{"issue":"1","key":"7229_CR137","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1038\/s42003-021-01786-y","volume":"4","author":"SI Kubota","year":"2021","unstructured":"Kubota SI, et al. Whole-organ analysis of TGF-\u03b2-mediated remodelling of the tumour microenvironment by tissue clearing. Commun Biol. 2021;4(1):294.","journal-title":"Commun Biol"},{"issue":"5","key":"7229_CR138","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1002\/cbin.10067","volume":"37","author":"H Chen","year":"2013","unstructured":"Chen H, et al. Direct TGF-\u03b21 signaling between activated platelets and pancreatic cancer cells primes cisplatin insensitivity. Cell Biol Int. 2013;37(5):478\u201384.","journal-title":"Cell Biol Int"},{"issue":"11","key":"7229_CR139","doi-asserted-by":"publisher","first-page":"e80780","DOI":"10.1371\/journal.pone.0080780","volume":"8","author":"Kalinichenko","year":"2013","unstructured":"Kalinichenko, Vladimir V, et al. Platelet P2Y12 is involved in murine pulmonary metastasis. PLoS ONE. 2013;8(11):e80780.","journal-title":"PLoS ONE"},{"issue":"7","key":"7229_CR140","doi-asserted-by":"publisher","first-page":"1884","DOI":"10.1053\/j.gastro.2015.07.064","volume":"149","author":"D Wang","year":"2015","unstructured":"Wang D, et al. Prostaglandin E2 promotes colorectal cancer stem cell expansion and metastasis in mice. Gastroenterology. 2015;149(7):1884-1895.e4.","journal-title":"Gastroenterology"},{"issue":"1","key":"7229_CR141","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12885-016-3018-2","volume":"17","author":"P Nandi","year":"2017","unstructured":"Nandi P, et al. PGE2 promotes breast cancer-associated lymphangiogenesis by activation of EP4 receptor on lymphatic endothelial cells. BMC Cancer. 2017;17(1):11.","journal-title":"BMC Cancer"},{"issue":"22","key":"7229_CR142","doi-asserted-by":"publisher","first-page":"32462","DOI":"10.18632\/oncotarget.8655","volume":"7","author":"P Guillem-Llobat","year":"2016","unstructured":"Guillem-Llobat P, et al. Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells. Oncotarget. 2016;7(22):32462\u201377.","journal-title":"Oncotarget"},{"issue":"1","key":"7229_CR143","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/ijc.28947","volume":"136","author":"S Gebremeskel","year":"2015","unstructured":"Gebremeskel S, et al. The reversible P2Y12 inhibitor ticagrelor inhibits metastasis and improves survival in mouse models of cancer. Int J Cancer. 2015;136(1):234\u201340.","journal-title":"Int J Cancer"},{"issue":"1\u20132","key":"7229_CR144","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10585-018-9874-1","volume":"35","author":"AJ Gareau","year":"2018","unstructured":"Gareau AJ, et al. Ticagrelor inhibits platelet-tumor cell interactions and metastasis in human and murine breast cancer. Clin Exp Metastasis. 2018;35(1\u20132):25\u201335.","journal-title":"Clin Exp Metastasis"},{"issue":"10","key":"7229_CR145","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1016\/j.cgh.2018.12.012","volume":"17","author":"A Rodr\u00edguez-Miguel","year":"2019","unstructured":"Rodr\u00edguez-Miguel A, et al. Clopidogrel and low-dose aspirin, alone or together, reduce risk of colorectal cancer. Clin Gastroenterol Hepatol. 2019;17(10):2024-2033.e2.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"7229_CR146","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.amjmed.2017.01.022","volume":"130","author":"A Leader","year":"2017","unstructured":"Leader A, et al. The effect of combined aspirin and clopidogrel treatment on cancer incidence. Am J Med. 2017;130(7):826\u201332.","journal-title":"Am J Med"},{"issue":"10","key":"7229_CR147","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.3390\/cancers11101468","volume":"11","author":"YC Kuan","year":"2019","unstructured":"Kuan YC, et al. Effects of aspirin or clopidogrel on colorectal cancer chemoprevention in patients with type 2 diabetes mellitus. Cancers (Basel). 2019;11(10):1468.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"7229_CR148","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.3390\/cancers12113215","volume":"12","author":"T Hayashi","year":"2020","unstructured":"Hayashi T, et al. Antiplatelet therapy improves the prognosis of patients with hepatocellular carcinoma. Cancers (Basel). 2020;12(11):3215.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"7229_CR149","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1158\/1055-9965.EPI-20-1292","volume":"30","author":"M Cairat","year":"2021","unstructured":"Cairat M, et al. Antiplatelet drug use and breast cancer risk in a prospective cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2021;30(4):643\u201352.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"7229_CR150","doi-asserted-by":"publisher","first-page":"e005795","DOI":"10.1161\/CIRCINTERVENTIONS.117.005795","volume":"11","author":"S Elmariah","year":"2018","unstructured":"Elmariah S, et al. Impact of clopidogrel therapy on mortality and cancer in patients with cardiovascular and cerebrovascular disease: a patient-level meta-analysis. Circulation Cardiovascular interventions. 2018;11(1):e005795.","journal-title":"Circulation. Cardiovascular interventions"},{"issue":"8","key":"7229_CR151","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/pds.3807","volume":"24","author":"B Hicks","year":"2015","unstructured":"Hicks B, et al. Clopidogrel use and cancer-specific mortality: a population-based cohort study of colorectal, breast and prostate cancer patients. Pharmacoepidemiol Drug Saf. 2015;24(8):830\u201340.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"7229_CR152","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.thromres.2018.12.014","volume":"174","author":"S Raposeiras-Roub\u00edn","year":"2019","unstructured":"Raposeiras-Roub\u00edn S, et al. Risk of cancer after an acute coronary syndrome according to the type of P2Y12 inhibitor. Thromb Res. 2019;174:51\u20138.","journal-title":"Thromb Res"},{"issue":"47","key":"7229_CR153","doi-asserted-by":"publisher","first-page":"47ra63","DOI":"10.1126\/scitranslmed.3001001","volume":"2","author":"P Duffau","year":"2010","unstructured":"Duffau P, et al. Platelet CD154 potentiates interferon-alpha secretion by plasmacytoid dendritic cells in systemic lupus erythematosus. Sci Transl Med. 2010;2(47):47ra63.","journal-title":"Sci Transl Med."},{"issue":"8","key":"7229_CR154","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1111\/j.1538-7836.2004.00854.x","volume":"2","author":"L Wang","year":"2004","unstructured":"Wang L, et al. Transcriptional down-regulation of the platelet ADP receptor P2Y(12) and clusterin in patients with systemic lupus erythematosus. J Thromb Haemost. 2004;2(8):1436\u201342.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"7229_CR155","doi-asserted-by":"publisher","first-page":"354","DOI":"10.15537\/smj.2016.4.14768","volume":"37","author":"G Harifi","year":"2016","unstructured":"Harifi G, Sibilia J. Pathogenic role of platelets in rheumatoid arthritis and systemic autoimmune diseases. Perspectives and therapeutic aspects. Saudi Med J. 2016;37(4):354\u201360.","journal-title":"Saudi Med J"},{"issue":"6","key":"7229_CR156","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s00296-018-4001-9","volume":"38","author":"ZM Lukasik","year":"2018","unstructured":"Lukasik ZM, Makowski M, Makowska JS. From blood coagulation to innate and adaptive immunity: the role of platelets in the physiology and pathology of autoimmune disorders. Rheumatol Int. 2018;38(6):959\u201374.","journal-title":"Rheumatol Int"},{"issue":"7","key":"7229_CR157","doi-asserted-by":"publisher","first-page":"e69093","DOI":"10.1371\/journal.pone.0069093","volume":"8","author":"O Frey","year":"2013","unstructured":"Frey O, et al. Erosive arthritis and hepatic granuloma formation induced by peptidoglycan polysaccharide in rats is aggravated by prasugrel treatment. PLoS ONE. 2013;8(7):e69093.","journal-title":"PLoS ONE"},{"issue":"10","key":"7229_CR158","doi-asserted-by":"publisher","first-page":"e26035","DOI":"10.1371\/journal.pone.0026035","volume":"6","author":"AE Garcia","year":"2011","unstructured":"Garcia AE, et al. Clopidogrel, a P2Y12 receptor antagonist, potentiates the inflammatory response in a rat model of peptidoglycan polysaccharide-induced arthritis. PLoS One. 2011;6(10):e26035.","journal-title":"PLoS One"},{"issue":"3","key":"7229_CR159","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.alit.2017.11.008","volume":"67","author":"T Takeda","year":"2018","unstructured":"Takeda T, et al. Recent advances in understanding the roles of blood platelets in the pathogenesis of allergic inflammation and bronchial asthma. Allergol Int. 2018;67(3):326\u201333.","journal-title":"Allergol Int"},{"issue":"4","key":"7229_CR160","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.3390\/ijms21041391","volume":"21","author":"A Mansour","year":"2020","unstructured":"Mansour A, et al. P2Y12 inhibition beyond thrombosis: effects on inflammation. International Journal of Molecular Sciences. 2020;21(4):1391.","journal-title":"International Journal of Molecular Sciences"},{"issue":"11","key":"7229_CR161","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1084\/jem.20091240","volume":"206","author":"S Paruchuri","year":"2009","unstructured":"Paruchuri S, et al. Leukotriene E4-induced pulmonary inflammation is mediated by the P2Y12 receptor. J Exp Med. 2009;206(11):2543\u201355.","journal-title":"J Exp Med"},{"issue":"2","key":"7229_CR162","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/jcmm.12727","volume":"20","author":"DH Suh","year":"2016","unstructured":"Suh DH, et al. P2Y12 antagonist attenuates eosinophilic inflammation and airway hyperresponsiveness in a mouse model of asthma. J Cell Mol Med. 2016;20(2):333\u201341.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"7229_CR163","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.jaci.2018.06.001","volume":"143","author":"TM Laidlaw","year":"2019","unstructured":"Laidlaw TM, et al. A trial of type 12 purinergic (P2Y12) receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol. 2019;143(1):316-324.e7.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"7229_CR164","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/jth.12779","volume":"13","author":"F Lussana","year":"2015","unstructured":"Lussana F, et al. Effect of prasugrel in patients with asthma: results of PRINA, a randomized, double-blind, placebo-controlled, cross-over study. J Thromb Haemost. 2015;13(1):136\u201341.","journal-title":"J Thromb Haemost"},{"issue":"8","key":"7229_CR165","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1111\/j.1538-7836.2008.03039.x","volume":"6","author":"SJ Mundell","year":"2008","unstructured":"Mundell SJ, et al. Rapid resensitization of purinergic receptor function in human platelets. J Thromb Haemost. 2008;6(8):1393\u2013404.","journal-title":"J Thromb Haemost"},{"issue":"9","key":"7229_CR166","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1182\/blood-2004-07-2893","volume":"105","author":"AR Hardy","year":"2005","unstructured":"Hardy AR, et al. P2Y1 and P2Y12 receptors for ADP desensitize by distinct kinase-dependent mechanisms. Blood. 2005;105(9):3552\u201360.","journal-title":"Blood"},{"issue":"11","key":"7229_CR167","doi-asserted-by":"publisher","first-page":"3932","DOI":"10.3390\/ijms21113932","volume":"21","author":"P Chaudhary","year":"2020","unstructured":"Chaudhary P, et al. Role of GRK6 in the regulation of platelet activation through selective G protein-coupled receptor (GPCR) desensitization. Int J Mol Sci. 2020;21(11):3932.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"7229_CR168","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/j.1538-7836.2011.04217.x","volume":"9","author":"B Nagy Jr","year":"2011","unstructured":"Nagy B Jr, et al. Contribution of the P2Y12 receptor-mediated pathway to platelet hyperreactivity in hypercholesterolemia. J Thromb Haemost. 2011;9(4):810\u20139.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"7229_CR169","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1124\/jpet.111.184143","volume":"339","author":"H Haberstock-Debic","year":"2011","unstructured":"Haberstock-Debic H, et al. A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist. J Pharmacol Exp Ther. 2011;339(1):54\u201361.","journal-title":"J Pharmacol Exp Ther"},{"key":"7229_CR170","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.thromres.2018.05.029","volume":"168","author":"J Koessler","year":"2018","unstructured":"Koessler J, et al. The role of agonist-induced activation and inhibition for the regulation of purinergic receptor expression in human platelets. Thromb Res. 2018;168:40\u20136.","journal-title":"Thromb Res"},{"key":"7229_CR171","doi-asserted-by":"publisher","first-page":"653149","DOI":"10.1155\/2014\/653149","volume":"2014","author":"MH Periayah","year":"2014","unstructured":"Periayah MH, et al. Glycoprotein IIb\/IIIa and P2Y12 induction by oligochitosan accelerates platelet aggregation. Biomed Res Int. 2014;2014:653149.","journal-title":"Biomed Res Int"},{"issue":"3","key":"7229_CR172","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s11239-006-9033-4","volume":"22","author":"G Shanker","year":"2006","unstructured":"Shanker G, et al. Nicotine upregulates the expression of P2Y12 on vascular cells and megakaryoblasts. J Thromb Thrombolysis. 2006;22(3):213\u201320.","journal-title":"J Thromb Thrombolysis"},{"issue":"9","key":"7229_CR173","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1161\/CIRCULATIONAHA.116.026995","volume":"136","author":"L Hu","year":"2017","unstructured":"Hu L, et al. Platelets express activated P2Y12 receptor in patients with diabetes mellitus. Circulation. 2017;136(9):817\u201333.","journal-title":"Circulation"},{"issue":"3","key":"7229_CR174","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1160\/TH16-04-0322","volume":"117","author":"Z Fejes","year":"2017","unstructured":"Fejes Z, et al. Hyperglycaemia suppresses microRNA expression in platelets to increase P2RY12 and SELP levels in type 2 diabetes mellitus. Thromb Haemost. 2017;117(3):529\u201342.","journal-title":"Thromb Haemost"},{"issue":"19","key":"7229_CR175","doi-asserted-by":"publisher","first-page":"5189","DOI":"10.1182\/blood-2010-09-299719","volume":"117","author":"S Nagalla","year":"2011","unstructured":"Nagalla S, et al. Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity. Blood. 2011;117(19):5189\u201397.","journal-title":"Blood"},{"issue":"2","key":"7229_CR176","first-page":"128","volume":"30","author":"B Szilagyi","year":"2019","unstructured":"Szilagyi B, et al. Role of sepsis modulated circulating microRNAs. EJIFCC. 2019;30(2):128\u201345.","journal-title":"EJIFCC"},{"key":"7229_CR177","doi-asserted-by":"publisher","first-page":"981841","DOI":"10.1155\/2015\/981841","volume":"2015","author":"R Shi","year":"2015","unstructured":"Shi R, et al. The emerging role of miR-223 in platelet reactivity: implications in antiplatelet therapy. Biomed Res Int. 2015;2015:981841.","journal-title":"Biomed Res Int"},{"issue":"6","key":"7229_CR178","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.thromres.2013.02.015","volume":"131","author":"R Shi","year":"2013","unstructured":"Shi R, et al. Decreased platelet miR-223 expression is associated with high on-clopidogrel platelet reactivity. Thromb Res. 2013;131(6):508\u201313.","journal-title":"Thromb Res"},{"issue":"1","key":"7229_CR179","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11239-013-1022-9","volume":"38","author":"YY Zhang","year":"2014","unstructured":"Zhang YY, et al. Decreased circulating microRNA-223 level predicts high on-treatment platelet reactivity in patients with troponin-negative non-ST elevation acute coronary syndrome. J Thromb Thrombolysis. 2014;38(1):65\u201372.","journal-title":"J Thromb Thrombolysis"},{"issue":"9","key":"7229_CR180","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1038\/nsmb.1651","volume":"16","author":"P Landry","year":"2009","unstructured":"Landry P, et al. Existence of a microRNA pathway in anucleate platelets. Nat Struct Mol Biol. 2009;16(9):961\u20136.","journal-title":"Nat Struct Mol Biol"},{"issue":"3","key":"7229_CR181","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1161\/CIRCRESAHA.114.305663","volume":"118","author":"D Kaudewitz","year":"2016","unstructured":"Kaudewitz D, et al. Association of MicroRNAs and YRNAs with platelet function. Circ Res. 2016;118(3):420\u201332.","journal-title":"Circ Res"},{"issue":"4","key":"7229_CR182","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1080\/09537104.2018.1457781","volume":"30","author":"M Zhou","year":"2019","unstructured":"Zhou M, et al. Long non-coding RNA metallothionein 1 pseudogene 3 promotes p2y12 expression by sponging miR-126 to activate platelet in diabetic animal model. Platelets. 2019;30(4):452\u20139.","journal-title":"Platelets"},{"issue":"12","key":"7229_CR183","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1161\/ATVBAHA.110.213702","volume":"30","author":"BH Rauch","year":"2010","unstructured":"Rauch BH, et al. Regulation of functionally active P2Y12 ADP receptors by thrombin in human smooth muscle cells and the presence of P2Y12 in carotid artery lesions. Arterioscler Thromb Vasc Biol. 2010;30(12):2434\u201342.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"4","key":"7229_CR184","doi-asserted-by":"publisher","first-page":"3774","DOI":"10.3892\/etm.2017.4955","volume":"14","author":"J-J Li","year":"2017","unstructured":"Li J-J, et al. Antiplatelet drug ticagrelor delays gastric ulcer healing in rats. Exp Ther Med. 2017;14(4):3774\u20139.","journal-title":"Exp Ther Med"},{"issue":"3","key":"7229_CR185","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1111\/j.1365-2362.2009.02089.x","volume":"39","author":"K Pels","year":"2009","unstructured":"Pels K, et al. Long-term clopidogrel administration following severe coronary injury reduces proliferation and inflammation via inhibition of nuclear factor-kappaB and activator protein 1 activation in pigs. Eur J Clin Invest. 2009;39(3):174\u201382.","journal-title":"Eur J Clin Invest"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-021-07229-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10557-021-07229-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-021-07229-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T04:11:36Z","timestamp":1673410296000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10557-021-07229-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,28]]},"references-count":185,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["7229"],"URL":"https:\/\/doi.org\/10.1007\/s10557-021-07229-4","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,28]]},"assertion":[{"value":"7 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}